Clinical Endpoints in Pragmatic Heart Failure Trials: From Data Collection to Clinical Endpoint Classification
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15366 ↗At a glance
Übersichtsarbeit in ESC Heart Failure, 2025. Written by Veraprapas Kittipibul and 13 co-authors. Institution: Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA. Major MEDLINE topics: Heart Failure, Pragmatic Clinical Trials as Topic, Endpoint Determination, Data Collection. 62 references. The full text is freely available (open access, CC BY-NC 4.0).
Topics: Herzinsuffizienz
Abstract (original language)
Clinical endpoint classification (CEC)—that is, evaluation of clinical events using pre-defined criteria—is commonly conducted in clinical trial operations to ensure systematic and consistent assessment of endpoints needed to assess the intervention's safety and efficacy. This is particularly relevant for heart failure (HF) trials given the subjective decision-making around hospitalizations and variation in how worsening HF events are managed (both in hospital and in ambulatory settings). Several CEC strategies have been adopted to address the growing need for pragmatic clinical trials that enhance generalizability and minimize research burden on trial sites and patients. This review summarizes common CEC strategies including the traditional approach, investigator-reported endpoints, CEC using real-world data and CEC utilizing large language models. We summarize CEC strategies used in recent HF pragmatic trials and present challenges and considerations for CEC in HF pragmatic trials from the selection of clinical endpoints and data collection to CEC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA.
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Population Health Research Institute, Hamilton, Ontario, Canada.
- Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
- Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
ORCID profiles: Veraprapas Kittipibul
Cite
APA
Kittipibul, V., Van Spall, H. G. C., Jones, W. S., Fudim, M., Mentz, R. J., Anstrom, K., Pitt, B., Desvigne-Nickens, P., Fleg, J. L., Hage, C., James, S., Held, C., Lund, L., & DeVore, A. (2025). Clinical Endpoints in Pragmatic Heart Failure Trials: From Data Collection to Clinical Endpoint Classification. ESC Heart Failure. https://doi.org/10.1002/ehf2.15366
Vancouver
Kittipibul V, Van Spall HGC, Jones WS, Fudim M, Mentz RJ, Anstrom K, et al. Clinical Endpoints in Pragmatic Heart Failure Trials: From Data Collection to Clinical Endpoint Classification. ESC Heart Failure. 2025. doi:10.1002/ehf2.15366
BibTeX
@article{Kittipibul2025,
author = {Kittipibul, Veraprapas and Van Spall, Harriette G C and Jones, William Schuyler and Fudim, Marat and Mentz, Robert J and Anstrom, Kevin and Pitt, Bertram and Desvigne-Nickens, Patrice and Fleg, Jerome L and Hage, Camilla and James, Stefan and Held, Claes and Lund, Lars and DeVore, Adam},
title = {Clinical Endpoints in Pragmatic Heart Failure Trials: From Data Collection to Clinical Endpoint Classification},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15366}
}
EUVIMED